CXA-201 and metronidazole + Meropenem

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Complicated Intra-abdominal Infection

Conditions

Complicated Intra-abdominal Infection

Trial Timeline

Dec 23, 2011 → Oct 15, 2013

NCT ID

NCT01445678

About CXA-201 and metronidazole + Meropenem

CXA-201 and metronidazole + Meropenem is a phase 3 stage product being developed by Merck for Complicated Intra-abdominal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT01445678. Target conditions include Complicated Intra-abdominal Infection.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01445678	Phase 3	Completed	Dec 23, 2011	Oct 15, 2013	Complicated Intra-abdominal Infection

Competing Products

20 competing products in Complicated Intra-abdominal Infection

See all competitors

Product	Company	Stage	Hype Score
ZY19489 + Ferroquine (FQ) + Placebo	Zydus Lifesciences	Phase 1	33
HRS-8427 + Imipenem and Cilastatin Sodium + HRS-8427 placebo + Imipenem and Cilastatin Sodium placebo	Jiangsu Hengrui Medicine	Phase 3	77
HRS -8427 + Imipenem and Cilastatin Sodium	Jiangsu Hengrui Medicine	Phase 2	52
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo	Merck	Phase 3	77
Vancomycin + Daptomycin + Semi-Synthetic Penicillin	Merck	Approved	85
CXA-101 + Ceftazidime	Merck	Phase 2	52
Ceftolozane/Tazobactam + Meropenem	Merck	Phase 2	52
Imipenem+Cilastatin/Relebactam	Merck	Phase 3	77
Daptomycin + Vancomycin	Merck	Approved	85
CXA-101/ tazobactam and metronidazole + meropenem plus saline placebo	Merck	Phase 2	52
CXA-201 + Levofloxacin	Merck	Phase 3	77
Ceftolozane/Tazobactam + Metronidazole + Meropenem + Placebo for Metronidazole	Merck	Phase 2	52
MK0826; ertapenem sodium + Comparator: ceftriaxone + metronidazole	Merck	Approved	85
MK0826, /Duration of Treatment : 8 Weeks + Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks	Merck	Phase 3	77
KLU156 + Coartem	Novartis	Phase 3	77
LYS228 + Standard of care therapy	Novartis	Phase 2	52
Artemether-lumefantrine (COA566)	Novartis	Phase 2/3	65
INE963	Novartis	Phase 2	52
KAE609 + SoC (Coartem) + KLU156	Novartis	Phase 2	52
KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation	Novartis	Phase 2	52

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved